Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Sponsor: Shanghai Escugen Biotechnology Co., Ltd
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with Systemic Lupus Erythematosus (SLE).
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-09-01
Completion Date
2028-09-30
Last Updated
2026-08-12
Healthy Volunteers
No
Conditions
Interventions
ESG206
Anti-BAFF-R Monoclonal Antibody
ESG206
Anti-BAFF-R Monoclonal Antibody
Placebo
Placebo
Locations (20)
Shenzhen Third People's Hospital
Shenzhen, Guangdong, China
Zhongshan Traditional Chinese Medicine Hospital
Zhongshan, Guangdong, China
Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Liupanshui Shougang Shuigang Hospital
Liupanshui, Guizhou, China
Affiliated Hospital of Hebei Engineering University
Handan, Hebei, China
Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Changde First People's Hospital
Changde, Hunan, China
Xiangya Hospital, Central South University
Changsha, Hunan, China
Loudi Central Hospital
Loudi, Hunan, China
Zhuzhou Central Hospital
Zhuzhou, Hunan, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Zibo Central Hospital
Zibo, Shandong, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China
Linfen Central Hospital
Linfen, Shanxi, China
Mianyang Central Hospital
Mianyang, Sichuan, China
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China
Huzhou Third People's Hospital
Huzhou, Zhejiang, China
Jinhua Municipal Central Hospital
Jinhua, Zhejiang, China
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China